Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BackgroundA significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewer...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Philipp Scheuerlein, Larissa Pietsch, Nadezhda Camacho-Ordonez, Veronika Reiser, Smita Patel, Siobhan O. Burns, Klaus Warnatz, Bodo Grimbacher
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2018-07-01
Rangatū:	Frontiers in Immunology
Ngā marau:	common variable immunodeficiency autoimmune thrombocytopenia intravenous immunoglobulin subcutaneous immunoglobulin immunoglobulin replacement therapy
Urunga tuihono:	https://www.frontiersin.org/article/10.3389/fimmu.2018.01656/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!